Release date: 2017-10-25
Following the FDA approval of the first blood glucose monitor that does not require fingertip blood collection, Abbott’s smartphone-compatible implantable heart monitor (ICM), the Confirm Rx, has been approved for FDA approval, and the heart monitor can be used on mobile phones. The application sends the data to the doctor according to a preset schedule, which greatly facilitates the patient, which is the first similar device approved by the US FDA.
It is understood that after the product is implanted in the patient, the heart rhythm data is transmitted to the smart phone via Bluetooth, and the patient can use the application myMerlin to view the data and record it at any time, thereby achieving continuous monitoring of the patient's heart rate. It is more helpful for doctors to keep track of the patient's condition.
Currently, this implanted heart monitor is used to assess symptoms such as palpitations that may be caused by arrhythmia, etc. In the future, it may also be used in patients with atrial fibrillation and patients at risk of ventricular arrhythmia.
Earlier this year, Abbott acquired St. Jude Medical for $25 billion, which operates two business areas: Cardiac Rhythm Management and Heart Valve Management, which focuses on heart rhythm management, heart disease. Learning and vascular access, as well as the market for heart valve disease management, St. Jude Medical Equipment has been a pioneer in cardiovascular medical technology since 1976, and through this acquisition, Abbott has also been approved. Confirm Rx device and myMerlin app.
Source: Medical Valley
Enoki Mushroom Extract;Snow Puf Mushroom Extract;Enokitake Concentrated Powder
Shaanxi Zhongyi Kangjian Biotechnology Co.,Ltd , https://www.zhongyiherbs.com